NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer

Lancet Oncol. 2016 Nov;17(11):1483-1484. doi: 10.1016/S1470-2045(16)30488-0. Epub 2016 Sep 28.

Authors

Nwamaka Umeweni¹, Helen Knight², Gary McVeigh²

Affiliations

¹ National Institute for Health and Care Excellence, Manchester M1 4BT, UK. Electronic address: [email protected].
² National Institute for Health and Care Excellence, Manchester M1 4BT, UK.

PMID: 27692477
DOI: 10.1016/S1470-2045(16)30488-0

No abstract available

Publication types

News

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / economics
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / economics
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / secondary
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / immunology
Carcinoma, Squamous Cell / mortality
Carcinoma, Squamous Cell / secondary
Cost-Benefit Analysis
Drug Approval
Drug Costs
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Lung Neoplasms / mortality
Lung Neoplasms / pathology
Practice Guidelines as Topic
Quality-Adjusted Life Years
Treatment Outcome
United Kingdom

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
necitumumab